Cardiff Oncology
CRDF
26 hedge funds and large institutions have $16.2M invested in Cardiff Oncology in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 1 closing their positions.
986% more call options, than puts
Call options by funds: $76K | Put options by funds: $7K
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
126% more capital inflows, than outflows
Capital inflows: $2.26M | Capital outflows: $1M
18% more funds holding
Funds holding: 22 → 26 (+4)
2.84% less ownership
Funds ownership: 18.49% → 15.65% (-2.8%)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgens Waterfall Vintiadis & Co
New York
|
+$1.69M |
| 2 |
D.A. Davidson & Co
Great Falls,
Montana
|
+$333K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$74.4K |
| 4 |
National Planning Corporation
El Segundo,
California
|
+$22.3K |
| 5 |
BlackRock Advisors
Wilmington,
Delaware
|
+$16.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
C WorldWide Group
Copenhagen,
Denmark
|
-$366K |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$336K |
| 3 |
Morgan Stanley
New York
|
-$206K |
| 4 |
Paloma Partners
Greenwich,
Connecticut
|
-$59K |
| 5 |
Tower Research Capital (TRC)
New York
|
-$17.5K |
CRDF Hedge Fund Activity: Q4 2014 in Review
26 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q4 2014, worth a combined $16.2M — up 1.6% from $16M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CRDF positions and 1 closed out — a net gain of 4 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Morgens Waterfall Vintiadis & Co, opening a new position worth an estimated $1.69M. The largest seller was C WorldWide Group, cutting an estimated $366K.
- 26 institutional investors held Cardiff Oncology (CRDF) as of Q4 2014, up from 22 in Q3 2014.
- Funds reported $16.2M of Cardiff Oncology stock for Q4 2014, up 1.6% quarter-over-quarter.
- 5 funds opened new Cardiff Oncology positions in Q4 2014 and 1 closed out, a net change of +4 holders.
- The largest Cardiff Oncology buyer in Q4 2014 was Morgens Waterfall Vintiadis & Co, an estimated $1.69M added.
- The largest Cardiff Oncology seller in Q4 2014 was C WorldWide Group, an estimated $366K sold.
Based on aggregated 13F filings for Q4 2014.